World’s first contact lenses that darken in bright light approved in US

Washington Last Updated at April 16, 2018

The (FDA) has approved the world’s first contact that automatically darkens when exposed to bright light.

The Oasys with Transitions Light Intelligent Technology are soft indicated for daily use to correct the of people with non-diseased eyes who are nearsighted (myopic) or farsighted (hyperopic).

They can be used by people with certain degrees of astigmatism, an abnormal curvature of the eye.

“This contact is the first of its kind to incorporate the that is used in eyeglasses that automatically darken in the sun,” said Malvina Eydelman, of Ophthalmic, and Ear, Nose and Throat Devices at the for Devices and Radiological Health.

The contain a photochromic additive that adapts the amount of visible light filtered to the eye based on the amount of ultra-violet light to which they are exposed.

This results in slightly darkened lenses in bright sunlight that automatically return to a regular tint when exposed to normal or dark lighting conditions.

The FDA reviewed scientific evidence including a clinical study of 24 patients that evaluated daytime and nighttime driving performance while wearing the 

The results of the study demonstrated there was no evidence of concerns with either driving performance or while wearing the lenses.

These contacts are intended for daily wear for up to 14 days. Patients should not sleep in these contact lenses, expose them to water or wear them longer than directed by an eye care professional.

These contacts should not be used as substitutes for UV protective eyewear, the FDA said.

“This innovation was born out of deep research into consumer lifestyle needs and fits our future-forward approach to caring for human sight,” said Xiao-Yu Song, for Vision, the company that developed the 

The product creates and defines an entirely new category of that will address unmet needs for patients, according to the company.

“After more than a decade of product development and numerous clinical trials involving more than 1,000 patients, we are excited to bring to market a solution to help wearers manage the changing light conditions they face every day in their modern, active lives,” Song said.( PTI )